AstraZeneca’s MedImmune subsidiary is to receive $92.5 million as part of a legal settlement involving its respiratory drug Synagis. PDL …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

